Methods
Background
Increased perioperative blood pressure (BP) variability in cardiac surgery is associated with negative clinical outcomes and increased health resource utilization (HRU). 1 Clevidipine is an intravenous (IV) ultrashort-active, easily titratable, arterial selective calcium channel blocker that allows for the precise control of BP.
2
The ECLIPSE studies evaluated the safety and efficacy of clevidipine in cardiac surgery and demonstrated that clevidipine is more effective than nitroglycerin and nitroprusside, and as effective as nicardipine in maintaining patients within a specified range of blood pressure during cardiac surgery.
3
Secondary analyses of these data showed that the use of clevidipine resulted in a shorter time to extubation and ICU length of stay which was estimated to reduce hospital costs by $921 per patient.
4
Study Objective
An economic model was developed to evaluate the impact on a hospital or health system budget of increased clevidipine usage within the distribution of IV antihypertensive (IVAH) use for the management of elevated blood pressure in the perioperative setting. We present here a representative scenario to illustrate the model functionality. 
IVAH Mix and Rate of Polypharmacy

Model Inputs
• Inputs for the model are taken from a combination of published literature and database analyses.
• The model uses estimates of 532 coronary artery bypass graft (CABG) procedures and 366 heart valve repair or replacement (HVR/r) cases per year based on an analysis of the HCUP inpatient sample, with rates of hypertension among these cases of 88% 5 (net of 468 CABG and 322 HVR/r cases managed with IVAH).
• The reference IVAH treatment distribution used in the representative scenario was determined from an analysis of the Premier research database 6 by surgical type. Table 1 presents estimates of IVAH usage for the CABG and HVR/r cases. Many patients included in the analysis received more than one IVAH during the hospital stay; the treatment distribution was normalized using the proportion of patients receiving each treatment and the total sample size to adjust the overall distribution.
• The projected distribution is estimated by increasing the proportion of cases using clevidipine and applying a proportional reduction to the remaining treatments included in this comparison.
• HRU inputs were obtained from analyses of the different treatment arms in the ECLIPSE studies 1, 7 (presented in Table 2 ). The dataset from the ECLIPSE trials includes patients undergoing either a CABG or HVR/r procedure, but these groups were analyzed as a pool. Health care costs associated with HRU were obtained from the Premier analysis.
6
• Estimates of the average amount of IVAH administered per patient were derived from the Premier analysis. (Table 3) • IVAH drug costs represent wholesale acquisition costs 8 but can be customized to reflect a given system's actual costs ( 
Model Output
• The model estimates the budget impact (IVAH treatment cost and HRU/follow-up event costs) of increasing the utilization of clevidipine.
• The results are computed either on a per patient basis or summed for annual evaluation points to a maximum time horizon of 3 years. The base case model analysis presents estimates for a 1 year projection in a US hospital system.
• The model includes 1-way sensitivity testing for a variety of the inputs, summarized as a tornado plot. 
Results
Limitations
• The model scope is limited to cost elements that are likely to be affected by the selection of IVAH perioperative therapy according to available evidence and therefore do not reflect the total cost of care.
• The model uses pooled data from the ECLIPSE clinical trials of clevidipine rather than individual comparisons. More sophisticated meta-analysis techniques could improve the precision of the input data describing the comparison between clevidipine and the competing treatments.
• The ECLIPSE studies evaluated a patient sample undergoing CABG or HVR/r procedures. The HRU data was not separated by procedure type: the model assumes the same HRU patterns for these two procedure types.
• Utilization of branded nicardipine could not be separated from generic nicardipine in the original inpatient dataset. The distribution in this scenario assumes equal use of the two products, but this input can be customized based on more detailed data for an individual health system.
Conclusions
• In this example case, a moderate increased use of clevidipine from 1% to 5% at the full WAC price of $200 was modeled.
• In an example health system with an annual CABG/HVR/r volume of 790, a minimal increase in IVAH costs was offset by savings in clinical and utilization costs thus predicting a net cost savings of $35,434 per year.
• The impact of peri-operative IVAH selection is demonstrated beyond the scope of IVAH acquisition cost through the impact of improved HRU and follow-up outcomes associated with reduced perioperative BP variability. 
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• The base case evaluates an example hospital that performs 468 CABG and 322 HVR/r cases requiring IVAH per year.
• Clevidipine usage in the reference IVAH distribution was minimal (0% in CABG; 1% in HVR/r). • The base case results (Table 4) predict a one year total cost of $19,045,453 with the largest proportion of costs from general ward, ICU and operative suite time (approx. 30%, 21%, and 20% respectively). One year IVAH costs totaled $93,958 or 0.5% of total costs. Increasing the proportion of cases receiving clevidipine to 5% for both procedures increased drug acquisition costs by $13,005 and decreased HRU-related costs by $48,439 for a net decrease in costs of $35,434 for one year.
• Under this scenario, there is a change in IVAH costs of approximately 14%, and a change in resource-use and follow-up costs of approximately -0.3% for a net change in the total budget for CABG and HVR/r cases of -0.2% • Converting these figures to a cost-per-case average, the model predicts total cost of $24,101 for the reference IVAH distribution vs. $24,056 for the projected distribution, a net difference of -$45 per case. The net savings is driven by the offset predicted in the healthresource/follow-up costs of $61 per case, on average, which exceeds the average net increase in IVAH acquisition cost of $16 per case.
• One-way sensitivity testing was executed on the clinical and health resource use elements of the model inputs (Figure 2) . The net budget impact result was not strongly affected by variation in the individual parameters of the model, it was most impacted by variation in the hospital resource consumption and 30-day event rates
